This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nugent, H. M. Articles by Edelman, E. R. Search for Related Content PubMed PubMed Citation Articles by Nugent, H. M. Articles by Edelman, E. R. Related Collections Cerebrovascular disease/stroke Genetics of cardiovascular disease Other Research

(Circulation Research. 2003;92:1068.)
© 2003 American Heart Association, Inc.

Reviews

Tissue Engineering Therapy for Cardiovascular Disease

Helen M. Nugent, Elazer R. Edelman

From the Harvard-MIT Division of Health Sciences and Technology (H.M.N., E.R.E.), Massachusetts Institute of Technology, Cambridge, Mass, and the Cardiovascular Division (E.R.E.), Brigham and Women’s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass.

Correspondence to Helen M. Nugent, PhD, Massachusetts Institute of Technology, Building 16, Room 325, Cambridge, MA 02139. E-mail ellenugent{at}attbi.com

The present treatments for the loss or failure of cardiovascular function include organ transplantation, surgical reconstruction, mechanical or synthetic devices, or the administration of metabolic products. Although routinely used, these treatments are not without constraints and complications. The emerging and interdisciplinary field of tissue engineering has evolved to provide solutions to tissue creation and repair. Tissue engineering applies the principles of engineering, material science, and biology toward the development of biological substitutes that restore, maintain, or improve tissue function. Progress has been made in engineering the various components of the cardiovascular system, including blood vessels, heart valves, and cardiac muscle. Many pivotal studies have been performed in recent years that may support the move toward the widespread application of tissue-engineered therapy for cardiovascular diseases. The studies discussed include endothelial cell seeding of vascular grafts, tissue-engineered vascular conduits, generation of heart valve leaflets, cardiomyoplasty, genetic manipulation, and in vitro conditions for optimizing tissue-engineered cardiovascular constructs.

Key Words: tissue engineering • cardiovascular system • heart valves • vascular grafts • cardiomyoplasty

This article has been cited by other articles:

				M. Yacoub and R. Nerem Introduction. Bioengineering the heart Phil Trans R Soc B, August 29, 2007; 362(1484): 1253 - 1255. [Full Text] [PDF]

				H. Methe, A. Groothuis, M. H. Sayegh, and E. R. Edelman Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in allo- and xenogeneic models FASEB J, May 1, 2007; 21(7): 1515 - 1526. [Abstract] [Full Text] [PDF]

				Outlook Commentaries Perspectives in Vascular Surgery and Endovascular Therapy, December 1, 2006; 18(4): 342 - 351. [PDF]

				E. Chen, J. D. Larson, and S. C. Ekker Functional analysis of zebrafish microfibril-associated glycoprotein-1 (Magp1) in vivo reveals roles for microfibrils in vascular development and function Blood, June 1, 2006; 107(11): 4364 - 4374. [Abstract] [Full Text] [PDF]

				E. R. McVeigh Emerging Imaging Techniques Circ. Res., April 14, 2006; 98(7): 879 - 886. [Abstract] [Full Text] [PDF]

				I. Vesely Heart Valve Tissue Engineering Circ. Res., October 14, 2005; 97(8): 743 - 755. [Abstract] [Full Text] [PDF]

				M. A. Costa and D. I. Simon Molecular Basis of Restenosis and Drug-Eluting Stents Circulation, May 3, 2005; 111(17): 2257 - 2273. [Full Text] [PDF]

				L. Formigli, F. Francini, A. Tani, R. Squecco, D. Nosi, L. Polidori, S. Nistri, L. Chiappini, V. Cesati, A. Pacini, et al. Morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture is favored by direct cell-cell contacts and relaxin treatment Am J Physiol Cell Physiol, April 1, 2005; 288(4): C795 - C804. [Abstract] [Full Text] [PDF]

				L. G. Melo, M. Gnecchi, A. S. Pachori, D. Kong, K. Wang, X. Liu, R. E. Pratt, and V. J. Dzau Endothelium-Targeted Gene and Cell-Based Therapies for Cardiovascular Disease Arterioscler Thromb Vasc Biol, October 1, 2004; 24(10): 1761 - 1774. [Abstract] [Full Text] [PDF]

				E. J. Armstrong and J. Bischoff Heart Valve Development: Endothelial Cell Signaling and Differentiation Circ. Res., September 3, 2004; 95(5): 459 - 470. [Abstract] [Full Text] [PDF]

				L.G Melo, M Gnecchi, A.S Pachori, K Wang, and V.J Dzau Gene- and cell-based therapies for cardiovascular diseases: current status and future directions Eur. Heart J. Suppl., September 1, 2004; 6(suppl_E): E24 - E35. [Abstract] [Full Text]

				W.-H. Zimmermann and T. Eschenhagen Tissue engineering of aortic heart valves Cardiovasc Res, December 1, 2003; 60(3): 460 - 462. [Full Text] [PDF]

				A. Tiwari, G. Hamilton, and A. M. Seifalian Tissue Engineering Therapy for Cardiovascular Diseases Circ. Res., July 25, 2003; 93 (2): e1 - e1. [Full Text] [PDF]